Triplicate determinations of glucose-6-phosphatase activity in the 37,000 x g fraction of human liver homogenates were made. Table I summarizes the results from 100 consecutive autopsies. Enzyme activity for 78 nonleukemic children was 95 f 6 6 (1 SD), and for 22 leukemic children was 17 & 12 (1 SD) (p c 0.001). I n the leukemic group there was no relation between the glucose-6-phosphatase activity with antileukemic drug therapy, the white blood cell count and the duration of the disease prior to death. The quantity of leukemic infiltrate in these livers varied, but there was no correlation between the extent of infiltration and enzyme activity. Several livers from leukemic children had no infiltrate and still had low glucose-6-phosphatase activities. One infant with liver glycogen disease had the expected reduction in glucose-6-phosphatase activity. A few children with other diseases (histiocytosis X, lupus erythematosis, aplastic anemia and retinoblastoma) had low enzyme activity in the liver.
in the liver.
The time interval, 2-24 hours, between death and autopsy had no demonstrable effect on enzyme activity. Enzyme activity in nonleukemic liver diminished 5 %/day after storage up to 10 days and did not change significantly in leukemic livers. When 10 % liver homogenates, or the 37,000 x g fraction, was stored for 4 weeks at -20°C the percent of the original activity at 1, 2, 3 and 4 weeks was 70 %, 65 %, 53 % and 53 % respectively.
A gradual, but significant, decline in human liver glucose-6-phosphatase activity occurs between birth and old age ( fig. 2 ). Several potential inhibitors of enzyme activity were tested. The results are summarized in table 11. Inhibition by p-chloromercuribenzoate and copper, and a lack of activation by magnesium are characteristic of this enzyme. Inhibition by sodium amytal was determined a t p H 7.5 for both the control and the amytal-containing assays because of the poor solubility of amytal a t p H 6.5. Table I11 summarizes the results of glucagon tolerance tests performed on leukemic children (7 in remission, 8 in relapse). I t is apparent that the blood sugar rose higher a t 15 and 30 minutes in the remission group than in the relapse group. The increase in both groups would probably be considered within the normal range, but the difference between them was significant (P <0.05). Lactate concentration was determined on each serum specimen and did not vary in response to glucagon, but was significantly higher in relapse than in remission. The means for the relapse and remission groups were significantly different (P < 0.001) at each time interval. Serum lactate was determined on one leukemic child 4 hours before death and was 150 meq/L.
Other enzyme activities which were determined on 8 leukemic and 8 nonleukemic livers after storage a t -20°C an average of 10 (controls) and 15 (leukemics) weeks are summarized in table IV.
T w o fresh leukemic a n d two nonleukemic livers were also assayed for each activity. T h e average of these assays were (leukemic, nonleukemic) : lactic dehydrogenase-0.44, 0.40; glucose-6-phosphate dehydrogenase-17.0, 8.5; adenosine triphosphatase 6.8, 14.0; inorganic pyrophosphatase 14, 33; fructose-I, 6-diphosphatase 6.0, 9.0. Four of the leukemic livers h a d n o detectable lactic dehydrogenase activity (below 0.02), while the other four h a d activities comparable to t h a t found in t h e nonleukemic livers. These d a t a m a y b e summarized as indicating t h a t liver from children with leukemia h a d reduced glucose-6-phosphatase, inorganic pyrophosphatase, a n d sometimes had reduced lactic dehydrogenase activity. Glucose-6-phosphate dehydrogenase was increased 2-3 fold. Adenosine triphosphatase, fructose-1, 6-diphosphatase a n d glycogen were present i n normal amounts.
Speculation
Altered carl,ohydrate metabolism i n children with terminal leukemia m a y have clinical manifestations (hypoglycemia a n d lactic acidosis) which a r e not commonly suspected. T h e possibility exists t h a t these metabolic changes a r e p a r t of t h e leukemic process rather t h a n a result of it a n d relate to t h e basic pathology of neoplasma.
ilftcr our 1st report [5] indicating that livcr glucose-6-phosphatasc was abnormally low in children who dicd of acutc lymphatic leukemia, 3 qucstions needed to bc answered.
1. Was this a unique finding in leukemia, or was it also found in other fatal diseases? 2. Was this a terminal cvcnt or was liver glucose-6-phosphatasc acti\.ity rcduced carlicr in Icukernia? 3. What associated cnzymatic abnormalitics wcrc present?This rcport summarizcs clata suggcsting partial answcrs to thesc qucstions.
Glucose-6-phosphatasc was assayccl by the mcthod dcscribcd by SW.+NSON [14] in which liver homogcnate and glucosc-6-phosphate werc incubated at pH 6.5 in 0.02 b1 malcatc buffer for 15 min at 37°C. Activity was then calculated as mltmoles phosphorus released from glucose-6-phosphatc/mg of protcinlmin. Duplicate assays ofall leukemic and most of the non-lcukemic li\.crs indicated that thc mcthod gave reproduciblc rcsults.
10 liver hornogcnatcs were prepared in 0.12 M KC1 at 0°C by homogenization at 800 rpm for 4-5 min with a glass-tcflon hornogenizcr. This homogenatc was divided into 3 fractions by successivc centrifugation at 600 x g for 10 min, 37,000 x g for 30 min, and a final supernatant. Thcsc 2 residucs werc resuspendcd in 0.12 M KC1 at a concentration of 10-15 mg/ml, arid were kept at 0°C until the assay. Each assay mixture containcd 0.1 ml of liver homogenate, 0.3 ml of maleate buffcr, and 0.1 ml of glucosc-6-phosphate, as described by SWANSON [14] . Protcin and phosphorus wcre detcrmined by the mcthods of LOWRY et 01.
[lo] and FISKE and SUBB.\ROW [GI.
Each liver specimcn was obtaincd at autopsy and the interval bctween dcath and autopsy was rccordcd. Drug therapy was also recorded for cach patient. ?'he clinical and pathologic diagnoses wcrc reviewed and only diagnoses confirmcd by pathological cxamination arc reported. When thc assay was not run immediatcly on the fresh liver specimen, it was stored at -20°C until the assay. Remission and relapse in thesc leukemic children was determined clinically and confirmed by bone marrow cxamination in cach child.
Glucagon tolerance tests wcrc run using 0.1 mg glucagon/kg body weight injected IV. Glucose and lactate wcre dctcrmined by standard methods [I, 111.
Thc liver homogeriatcs were also assayed for adenosine triphosphatase 181 and inorganic pyrophosphatase [I31 activity. Supernatant fractions obtained by ccntrifuging livcr homogcnate at 1 0 0 , 0 0 0~ g for 30 min in a Spinco Model L Ultracentrifuge, wcre assayed for fructose-1,6-diphosphatase [I 71, lactic dehydrogcnase [17] , and glucose-6-phosphate dchydrogcnase [7] . Glycogen was determined using the anthrone method describcd by VAN DER VIES [16] .
Triplicatc assays of glucose-6-phosphatasc in a human livcr homogenate wcrc run at 37OC and pH 6.5 for 0, 5, 10 and 15 min incubation times. Thc inorganic phosphorus liberated from glucose-6-phosphate by a constant amount of liver homogenatc was 0, 1.3, 2.1 and 3.0 /tmoles, respectively. The p H optimum of the 37,000 x g fraction of liver homogenate was evaluated by substituting 0.1 M buffers for the maleate butyer in the assay mixture. Duplicate assays (15 min incubation at 37°C) at p H 4.5, 5.0, 5.5 (acetate), 6.0, 6.5, 7.0 (maleate), 8 and 9 (tris-Cl) were run and the glucose-6-phosphatase activity (mitmoles P/mg protein/min) was 6, 8, 144, 163, 166, 156, 100 and 39, respectively. Duplicate assays a t 20° C, 30' C, 37' C, 42" C, 50" C and 60°C were run at p H 6.5 using the 37,000 x g fraction of liver homogenate and the activities were 33, 117, 169, 172, 108 and 0, respectively. The difference between leukemia and nonleukemia is significant, P -r 0.01, at each time interval.
leukemic children was 9 5 1 6 6 (I SD), and for 22 leukemic children was 17& 12 (1 SD). The difference between these two means was significant (P < 0.001).
Within the leukemic group, attempts were made to correlate the glucose-6-phosphatase activity with the antilcukemic drug therapy, the white blood cell count, and the duration of the leukemia prior to death. No relationship between these 3 variables and the activity was found. Two children with leukemia had received no antileukemia drugs, and had reduced enzyme activity (1 1, 37). The quantity of leukemic infiltrate in these livers varied, but there was no correlation between the extent of infiltration and the activity. Several livers from lcukemic children had no infiltrate and still had low glucose-6-phosphatase activities. One infant with glycogen storage disease had the expected reduction in liver glucose-6-phosphatase. A few children with other diseases were found to havc low liver glucose-6-phosphatase (histiocytosis X, lupus erythematosis, aplastic anemia and retinoblastoma). The time interval, 2-24 hours between death and autopsy had no demonstrable effect on enzyme activ-. .
itv. This time interval was recorded for each case, and the mean enzymr activity did not vary when the interval was 0 4 hours (3 1 cases), 7-12 hours (29 cases), 13-18 hours (25 cases), and 19-24 hours (15 cases). Most assays were run promptly, and in others the liver was stored at -20°C as indicated in figure 1 . Enzyme activity diminished 5%/day up to 10 days in nonleu-kemic liver, and did not significantly change in the leukrmic livers. \Yhen 10 % liver homogenate, or the 37,000 Y g fraction, was stored for 4 weeks at -20' C thr : : , of thr original activity at 1,2, 3 and 4 weeks was 70 :&, 65 %, 53 : & and 53 0/,, respectively. The effect ofage on the glucose-6-phosphatasc activity is indicated in figure 2 . A gradual, but significant, declinc in human livcr glucosc-6-phosphatase activity occurs bctwecn birth and old agr.
Sevcral potential inhibitors were tested and the results are summarized in table 11. Inhibition by p-chloromrrcuribcnzoate and copper, and the lack of activation by magnrsium arc characteristic of this enzyme. Inhibition by sodium amytal was determined at p H 7.5 for both the control and the amytal-containing assays because of the poor solubility of amytal at pH 6.5. ~Ymytal is a known inhibitor of DPNH oxidasc activity and the fractionation reported by MOURY and CRANE 1121 of electron transport components in liver suggested their presence in the 37,000 x g fraction. Novobiocin is known to inhibit the microsomal cnzyme glucuronyl transferase [9] , and its inhibition of glucose-6-phosphatase, another microsomal enzyme raised the possibility of a structural similarity between these two enzymes. Chloramphrnicol, a drug which can lower glucose-6-phosphatase activity when administered to ducks [4] , was not an inhibitor at lQ4 M. Table 111 summarizes the results of glucagon toleranca tests performed on leukemic children (7 in remission, 8 in relapse). It is apparent that the blood sugar rose higher at 15 and 30 min in the remission group than in the relapse group. The increase in both groups would probably be considered within the normal range, but the difference between them was significant (P < 0.05). Lactate concentration was determined on each serum specimen and did not vary in response to glucagon, but was significantly higher in relapse than in remission. The means for the relapse and rcmission groups were significantly different (P < 0.001) at each time interval. Serum lactate was determined on one leukemic child 4 hours before death and was 150 mEq/l. lactate at all time intervals were significant (P <0.001).
The numbrr of patients is indicated in parentheses. Table IV summarizes the results of othcr enzyme activities which werc dctcrmincd on 8 leukemic and 8 nonlcukcmic livers. Glucose-6-phosphatase activity was dctcrmincd on the day of the autopsy. The other mcasurcments were made on liver spccimcns which had been stored at -20' C an avcrage of 10 (controls) and 15 (leukemics) weeks. Two fresh leukemic and two nonlcukemic livers were also assayed for cach activity. The avcrage of these assays were (leukemic, nonleukemic): lactic dehydrogenase 0.44, 0.40; glucose-6-phosphate dchydrogenasc 17.0, 8.5; adenosine triphosphatase 6.8, 14.0; inorganic pyrophosphatase 14, 33; fructose-1,6-diphosphatase-6.0, 9.0. Four of the lcukcmic livers summarized in table IV had no dctcctablc lactic dehydrogenase (below 0.02), while the other four had activities comparable to the nonleukemic livcrs. These data may be summarized as indicating that liver from children with leukemia had reduced glucose-6-phosphatase, inorganic pyrophosphatase, and sometimes had reduced lactic dehydrogcnasc. Glucose-6-phosphate dchydrogenase was increased 2-3 fold. Adenosine triphosphatase, fructose-1,6-diphosphatasc and glycogen were present in normal amounts.
Liver glucosc-6-phosphatase assays for this study were all done at pH 6.5 using the residue from liver homogcnate that sediments between 600 x g and 37,000 x g. This procedure has the advantage of providing a 2-3 fold purification of the activity, making the assay more sensitive, and also tends to reduce errors caused by soluble non-specific phosphatases.
These data indicate that 22 consecutivc autopsy livcr specimens from children with leukemia were deficient in glucose-6-phosphatase activity. Among nonleukemics, aplastic anemia (3), histiocytosis (2), glycogen storage disease (I), lupus erythcmatosis (1) and occasional patients with heart disease, uremia, and pneumonia also had reduced liver glucose-6-phosphatasc activity. Insufficient patients were analyzed for most of thcsc diseases to know how commonly it occurs in them.
The time when liver glucose-6-phosphatase becomes reduced during the course of childhood leukemia has not been established. I t was not possible to obtain biopsy livcr specimens from leukemic children.
Data from the glucagon tolerance tests indicate that this enzyme activity may be reduced at the time of relapse. Reduction of liver glycogen stores and reduction of othcr glycogenolytic enzyme activities could also account for these data.
The other enzymes which were studied in this report indicated that liver lactic dehydrogenase was markedly reduced in some leukemics. When correlated with the finding by BIERMAN et al. [3] that serum lactic dehydrogenase is commonly elevated in leukemia, it would seem to be reasonable to suggest that part of the increased serum lactic dehydrogenase may have come from the liver. Increascd liver glucose-6-phosphate dehydrogenase activity was found in the children with leukemia. One possible mechanism for this could come from the reduced glucose-6-phosphatase activity. I t is possible that increased intracellular glucose-6-phosphate may induce enzymes like glucose-6-phosphate dehydrogenase for which it is the substrate.
Elevated serum lactatc concentration in lcukemic children during relapse, and much greater increases just prior to death, is similar to the situation in leukemic Liver glucose-6-phosphatase a n d carbohydrate metabolism in childhood leukemia 121 chickcns [2] . During the 24 hours prior to death, chickcns infectcd with myeloblastosis virus developed a suddcn reduction in blood sugar concentration.
TKANQUADA [I51 recently reviewed 71 reported cases oflactic acidosis, which included 9 leukemics and many patients with liver diseases. There were also patients with hcart and kidney discascs. The data in the prcsent study would suggest that lactic acidosis may be very common in leukemia, and relatively rare in hcart and kidney discasc.
'The cause for liver glucose-6-phosphatasc reduction in lcukcniia is unknown at present, but does not seem to be relatctl to the drug therapy. Since leukemic childrcn frcqucntly die of bacterial sepsis, the effect of sepsis on livcr glucose-6-phosphatasc has been evaluztcd in animals [4] . Prolonged (6 days) sepsis with S. aureus was notcd to significantly reduce rat liver glucosc-6-phosphatase activity. Thcre was no significant change in activity aftcr a single lethal i.p. injection of S. nltrercs, or after ti days sepsis with Pscudomonas.
Therefore, bacterial sepsis may be one factor contributing to the reduced livcr glucosc-6-phosphatase in leukcmia. The magnitude of this effect varies with the duration of the sepsis, and with the infecting organism. The 8 children who died of sepsis and meningitis had normal livcr glucosc-6-phosptiatasc, however.
Liver glucosc-6-phosphatasc activity was abnormally low in evcry child in which it was measured (22 children) who died of leukcmia. This enzyme activity was also reduccd in children who died of aplastic anemia, and occasionally in other discascs. Aging was associatcd with a significant declinc in li\w glucose-6-phosphatasc activity. :issays on 8 leukemic and 8 control livers indicated that lactic dchydrogenasc was also reduccd in leukemia, and that glucose-6-phosphate dchydrogcnase was elevated. Glucagon tolerance tests indicated that leukemic children in relapse have significantly less elevation in blood glucose than those in remission. Serum lactate concentration was significantly higher when the leukemic child was in relapse than in remission.
